Advances in prostate cancer biomarker research

Aims and objectives of this presentation
There is an increasing interest in the role of truncated androgen receptors in prostate cancer. These potentially very important biomarkers have been identified in several publications, however scientific consensus has to be reached. In addition, controversies on activated transcription factors as biomarkers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:18
Prostate cancer biomarkers: What’s new?
H.G. Lilja, New York (US)

*1064 Delivery of precision medicine in advanced prostate cancer using circulating tumour cells
By: Rhee H.,1 Gunter J.2, Javanovic L.2, Williams E.2, Hollier B.2, Nelson C.2, Vela I.3
Institutes: Princess Alexandra Hospital/Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, 2 Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

*1065 Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer
By: Josefsson A., Damber J-E., Welén K.
Institutes: Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Dept. of Urology, Gothenburg, Sweden

*1067 SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer
Institutes: Academic Urology Group, Dept. of Urology, Cambridge, United Kingdom, 2Neal Laboratory, Dept. of Uro-Oncology, Cambridge, United Kingdom, 3Carroll Laboratory, Cambridge Institute CRUK, Cambridge, United Kingdom, 4Addenbrooke's Trust University of Cambridge, Dept. of Pathology, Cambridge, United Kingdom, 5Biomarker Group, Cambridge Institute CRUK, Cambridge, United Kingdom

*1068 Expression of pSTAT3 in prostate cancer metastases from different organs
By: Don-Doncow N.1, Marginean F.1, Morrissey C.2, Hellsten R.1, Bjartell A.1
Institutes: Lund University Hospital, Dept. of Translational Medicine Malmö, Malmö, Sweden, 2University of Washington, Dept. of Urology, Seattle, United States of America

*1069 Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer
By: Schanz M.1, Hennenlotter J.1, Dlugosch J.1, Kuehs U.1, Dettmer M.2, Schilling D.3, Schwentner C.1, Stenzl A.1, Todenhöfer T.1
Institutes: Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 2Universitätsklinik Bern, Dept. of Pathology, Berne, Germany, 3Isar Klinikum, Dept. of Urology, Munich, Germany
**Poster Session 84**

*1070* Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients

**By:** Teishima J.¹, Nagamatsu H.¹, Shoji K.¹, Yamanaka R.¹, Kobatake K.¹, Kitano H.¹, Goto K.¹, Shinmei S.¹, Hayashi T.¹, Oue N.², Yasui W.², Matsubara A.¹

**Institutes:** Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan

*1071* The role of genomic classifier to assess post-operative metastatic risk for prostate cancer patients based on final pathology characteristics

**By:** Woodlief T. L., Rocco B., Ramharack R., Gnapani H., Ogaya G., Mouravieve V., Patel V.

**Institutes:** Florida Hospital, Global Robotics Institute, Celebration, United States of America

*1072* A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer

**By:** Heck M.¹, Thalgott M.¹, Schmid S.¹, Oh W.², Gong Y.², Wang L.², Zhu J.³, Seitz A-K.¹, Porst D.¹, Höppner M.¹, Retz M.¹, Gschwend J.¹, Nawroth R.¹

**Institutes:** Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, ²Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Hematology/Oncology, New York, United States of America, ³Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Genetic and Genomic Sciences, New York, United States of America

*1073* Prostate cancer copy number score predicts metastatic disease

**By:** Van Den Broeck T.¹, Gevaert T.¹, Prekovic S.², Smeets E.², Helsen C.², Lambrechts D.³, Boeckx B.³, Joniau S.¹, Claessens F.²

**Institutes:** University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³KU Leuven, Laboratory For Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium

*1074* Microseminoprotein-beta expression in different stages of prostate cancer

**By:** Sjöblom L², Saramäki O.², Annala M.², Leinonen K.², Nättinen J.², Tolonen T.³, Wahlfors T.², Nykter M.², Bova G.², Schleutker J.², Tammela T.¹, Lilja H.², Visakorpi T.²

**Institutes:** ¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²University of Tampere, BioMediTech, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴University of Turku, BioMediTech, Tampere, Finland

*1075* PD-L1 expression in castration-resistant prostate cancer (CRPC)

**By:** Fankhauser C.¹, Schüffler P.², Gillessen S.³, Omlin A.³, Hermanns T.¹, Poyet C.⁴, Sulser T.¹, Moch H.⁴, Wild P. J.⁴

**Institutes:** University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²Memorial Sloan Kettering Cancer Center, The Thomas Fuchs Lab, New York, United States of America, ³Cantonal Hospital, St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland, ⁴University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland